The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Allogene Therapeutics, Inc. Common Stock 019770106   8,037,789 1,798,163 SH   SOLE   1,798,163 0 0
Centessa Pharmaceuticals plc Ordinary Shares 152309100   44,429,544 3,931,818 SH   SOLE   3,931,818 0 0
Dyne Therapeutics, Inc. Common Stock 26818M108   11,568,897 407,499 SH   SOLE   407,499 0 0
Kronos Bio, Inc. Common Stock 50107A104   3,594,908 2,765,314 SH   SOLE   2,765,314 0 0
Kyverna Therapeutics, Inc. Common Stock 501976104   112,374,272 4,523,924 SH   SOLE   4,523,924 0 0